134 related articles for article (PubMed ID: 12128165)
1. Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice.
Leusch A; Volz A; Müller G; Wagner A; Sauer A; Greischel A; Roth W
Eur J Pharm Sci; 2002 Aug; 16(3):119-28. PubMed ID: 12128165
[TBL] [Abstract][Full Text] [Related]
2. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
4. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
[TBL] [Abstract][Full Text] [Related]
5. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
Dagenais C; Zong J; Ducharme J; Pollack GM
Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin.
Goralski KB; Hartmann G; Piquette-Miller M; Renton KW
Br J Pharmacol; 2003 May; 139(1):35-48. PubMed ID: 12746221
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice.
Kawahara M; Sakata A; Miyashita T; Tamai I; Tsuji A
J Pharm Sci; 1999 Dec; 88(12):1281-7. PubMed ID: 10585223
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test.
Lötsch J; Tegeder I; Angst MS; Geisslinger G
Life Sci; 2000 May; 66(24):2393-403. PubMed ID: 10864101
[TBL] [Abstract][Full Text] [Related]
10. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
[TBL] [Abstract][Full Text] [Related]
11. The anthelminthic agent albendazole does not interact with p-glycoprotein.
Merino G; Alvarez AI; Prieto JG; Kim RB
Drug Metab Dispos; 2002 Apr; 30(4):365-9. PubMed ID: 11901088
[TBL] [Abstract][Full Text] [Related]
12. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
14. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
[TBL] [Abstract][Full Text] [Related]
15. P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats.
Zhang Y; Wang C; Liu Z; Meng Q; Huo X; Liu Q; Sun P; Yang X; Sun H; Ma X; Liu K
Pharmacol Rep; 2018 Apr; 70(2):243-250. PubMed ID: 29475007
[TBL] [Abstract][Full Text] [Related]
16. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
17. Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats.
Nielsen CU; Abdulhussein AA; Colak D; Holm R
Int J Pharm; 2016 Nov; 513(1-2):78-87. PubMed ID: 27601334
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.
Chen C; Hanson E; Watson JW; Lee JS
Drug Metab Dispos; 2003 Mar; 31(3):312-8. PubMed ID: 12584158
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]